Saturday 17 October 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.
24.42
0.53
−2.12%
Follow NRIX
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
10.28 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.10 | 52.54 | 24.24 | 17.45 | |
P/FCF ratio |
7.78 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
4.67 | (20.00) | (24.20) | (21.61) | |
P/B ratio |
2.97 | 4.80 | 3.62 | 2.72 | |
Price to Tangible BV |
2.97 | 4.80 | 3.62 | 2.72 | |
EV/Sales |
2.60 | 40.48 | 16.71 | 10.39 | |
EV/EBITDA |
6.19 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
4.82 | (5.07) | (4.61) | (3.50) | |
EV/FCF |
4.94 | (4.89) | (4.41) | (3.31) | |
Quick Ratio |
8.17 | 6.16 | 5.86 | 6.86 | |
Current Ratio |
8.44 | 6.34 | 6.01 | 7.02 | |
Net Debt/EBITDA |
(1.86) | 4.91 | 6.09 | 6.68 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.82 | 0.07 | 0.11 | 0.12 | |
Operating CF/Net income |
1.12 | 1.08 | 0.82 | 0.87 | |
Capex/Depreciation |
(0.39) | (0.50) | (0.28) | 0.90 | |
Research and Development Expense of Revenue |
11.78% | 969.29% | 1,345.76% | 611.50% | |
Selling, General and Administrative Expense of Revenue |
5.10% | 172.44% | 233.69% | 100.52% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.60% | 125.93% | 150.42% | 66.92% | |
Graham Net Nets |
0.30 | 0.17 | 0.23 | 0.31 | |
Graham Number |
22.13 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
9.73% | (19.84%) | (19.99%) | (17.98%) | |
Free Cash Flow Yield |
12.86% | (15.76%) | (15.62%) | (17.98%) | |
Revenue per Share |
6.03 | 0.08 | 0.06 | 0.16 | |
Operating CF per Share |
5.52 | (0.87) | (0.65) | (0.78) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.06) | |
Free Cash Flow per Share |
5.51 | (0.89) | (0.66) | (0.84) | |
Cash per Share |
9.40 | 3.99 | 4.91 | 6.84 | |
Shareholders Equity per Share |
8.68 | 3.62 | 4.37 | 6.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.68 | 3.62 | 4.37 | 6.22 | |
Free Cash Flow |
614.24 | (98.51) | (72.96) | (72.96) | |
Working Capital |
972.95 | 384.46 | 462.20 | 520.35 | |
Capital Expenditures |
(1.39) | (1.94) | (1.04) | (5.13) | |
Net Current Asset Value |
876.71 | 323.57 | 399.16 | 457.43 | |
EV/EBIT |
6.31 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.21 | 0.17 | 0.38 | |
Price to Operating Income |
9.93 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.60 | — | — | — | |
Average Payables |
20.80 | 9.08 | 9.35 | 11.35 | |
Average Assets |
858.89 | 563.55 | 625.59 | 678.74 | |
Average Common Equity |
670.28 | 425.12 | 480.91 | 532.87 |
Columns are period end dates · fundamentals updated 15 Oct 2026